Analysts See $-0.48 EPS for AMAG Pharmaceuticals, Inc. (AMAG)

April 20, 2018 - By Hazel Jackson

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) LogoInvestors sentiment decreased to 0.9 in 2017 Q4. Its down 0.54, from 1.44 in 2017Q3. It fall, as 29 investors sold AMAG Pharmaceuticals, Inc. shares while 53 reduced holdings. 24 funds opened positions while 50 raised stakes. 37.72 million shares or 5.64% less from 39.98 million shares in 2017Q3 were reported.
Finance Architects Inc, New Jersey-based fund reported 200 shares. Connor Clark & Lunn Investment Mgmt owns 738,845 shares or 0.06% of their US portfolio. Adams Diversified Equity Fund has invested 0.02% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Citigroup reported 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Moreover, Shell Asset has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 8,541 shares. Comerica Bank, a Michigan-based fund reported 36,254 shares. Alliancebernstein L P owns 48,553 shares. New York-based Interest Gru Incorporated has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). 27,812 are owned by Barclays Public Ltd Company. Federated Investors Pa owns 94,659 shares. The New York-based State Teachers Retirement Sys has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Moreover, Teachers Retirement Of The State Of Kentucky has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Prelude Cap Mgmt Limited Liability Company invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Swiss Financial Bank owns 56,157 shares or 0% of their US portfolio. Ironwood Invest Management Ltd Liability Corp has 34,071 shares.

Since February 23, 2018, it had 0 buys, and 1 sale for $16,016 activity.

Analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report $-0.48 EPS on May, 1.They anticipate $0.58 EPS change or 54.72 % from last quarter’s $-1.06 EPS. After having $0.10 EPS previously, AMAG Pharmaceuticals, Inc.’s analysts see -580.00 % EPS growth. The stock decreased 4.57% or $0.95 during the last trading session, reaching $19.85. About 476,457 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has declined 16.25% since April 20, 2017 and is downtrending. It has underperformed by 27.80% the S&P500.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 8 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. AMAG Pharmaceuticals had 17 analyst reports since October 23, 2017 according to SRatingsIntel. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Hold” rating given on Thursday, February 1 by Cantor Fitzgerald. The firm earned “Hold” rating on Tuesday, February 27 by Cantor Fitzgerald. The stock has “Hold” rating by Cowen & Co on Tuesday, February 27. The firm has “Hold” rating given on Wednesday, February 14 by Piper Jaffray. The stock has “Hold” rating by Piper Jaffray on Thursday, January 18. Jefferies maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Friday, November 3 with “Buy” rating. The rating was maintained by Morgan Stanley with “Overweight” on Wednesday, February 28. The firm has “Buy” rating given on Thursday, February 15 by Janney Capital. Cantor Fitzgerald maintained the stock with “Hold” rating in Thursday, November 2 report. The firm earned “Buy” rating on Thursday, February 15 by Jefferies.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for women??s health, anemia management, and cancer supportive care in the United States. The company has market cap of $676.67 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: